Supported by Alexion Phamaceuticals, Macula Vision Research Foundation, National Institutes of Health (NIH) Center Core Grant P30EY014801, Research to Prevent Blindness, Department of Defense (W81XWH-09-1-0675), and a grant from Carl Zeiss Meditec, Inc.
Disclosure: P.F. Stetson, Carl Zeiss Meditec, Inc. (I, E), P; Z. Yehoshua, None; C.A.A. Garcia Filho, None; R. Portella Nunes, Carl Zeiss Meditec, Inc. (F); G. Gregori, Carl Zeiss Meditec, Inc. (F); P.J. Rosenfeld, Acucela (C), Advanced Cell Technology (F), Alexion Pharmaceuticals (F), Bayer Healthcare Pharmaceuticals (C), Boehringer Ingelheim (C), Chengdu Kanghong Biotech (C), GlaxoSmithKline (F) Oraya (C), Sanofi/Genzyme (C), ThromboGenics (C), Carl Zeiss Meditec, Inc. (F)